Literature DB >> 9024724

Proliferation index as a predictor of prognosis in malignant gliomas of childhood.

I F Pollack1, J W Campbell, R L Hamilton, A J Martinez, M E Bozik.   

Abstract

BACKGROUND: The prognosis for children with high grade gliomas remains somewhat unpredictable because histologic features alone provide an imperfect assessment of the biologic behavior of a given lesion. Whereas some patients experience prolonged disease control after surgery and adjuvant therapy, others with lesions that appear comparable exhibit rapid disease progression and death.
METHODS: Because proliferative activity may provide a potential correlate of biologic aggressiveness, the authors examined the relationship between MIB-1 labeling index and outcome in a series of 29 archival pediatric malignant nonbrainstem gliomas from patients treated consecutively at the study institution between 1975 and 1992, in which clinical, histologic, diagnostic, and therapeutic parameters were previously defined. Three patients who died perioperatively were excluded from outcome analyses. All tumors were rereviewed by two neuropathologists and classified as Grade 3 or 4 lesions based on contemporary guidelines.
RESULTS: Among the specimens from the 26 patients who survived the perioperative period, a striking difference in outcome was apparent between tumors with MIB-1 indices < 12 (n = 10) and those with indices > 12 (n = 16). Median progression free survival was >48 months in the low MIB-1 group compared with only 6 months in the high MIB-1 group (P = 0.014, rank-sum test). Median overall survival was >48 months in the low MIB-1 group compared with only 16 months in the high MIB-1 group (P = 0.012). MIB-1 index remained associated with survival after taking into account the effect of resection extent, which also correlated strongly with outcome in this cohort. Although MIB-1 index was associated with histopathologic grade (Grade 3: 11.9 +/- 9.7 vs. Grade 4: 27.3 +/- 19.0; P = 0.015, Fisher's exact test), it proved to be a much stronger predictor of outcome than histology.
CONCLUSIONS: MIB-1 index may supplement routine histologic classification as a means for improving the accuracy of predicting the biologic behavior of childhood malignant gliomas and may provide a basis for stratifying patients in future malignant glioma studies and refining therapeutic decision-making.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9024724

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas.

Authors:  Craig Horbinski; Ronald L Hamilton; Yuri Nikiforov; Ian F Pollack
Journal:  Acta Neuropathol       Date:  2010-01-01       Impact factor: 17.088

Review 2.  Pediatric giant cell glioblastoma: a case report and review of the literature.

Authors:  I De Prada; F Cordobés; D Azorín; T Contra; I Colmenero; I Glez-Mediero
Journal:  Childs Nerv Syst       Date:  2005-07-06       Impact factor: 1.475

Review 3.  Risk assignment in childhood brain tumors: the emerging role of molecular and biologic classification.

Authors:  Ian F Pollack; Jaclyn Biegel; Allan Yates; Ronald Hamilton; Sydney Finkelstein
Journal:  Curr Oncol Rep       Date:  2002-03       Impact factor: 5.075

4.  Proliferative and metabolic markers in incompletely excised pediatric pilocytic astrocytomas--an assessment of 3 new variables in predicting clinical outcome.

Authors:  Linda R Margraf; Lynn Gargan; Yasmeen Butt; Nirupa Raghunathan; Daniel C Bowers
Journal:  Neuro Oncol       Date:  2011-06-08       Impact factor: 12.300

5.  Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases.

Authors:  C H Rickert; R Sträter; P Kaatsch; H Wassmann; H Jürgens; B Dockhorn-Dworniczak; W Paulus
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

6.  Proliferative activity as measured by MIB-1 labeling index and long-term outcome of visual pathway astrocytomas in children.

Authors:  T Czech; I Slavc; M Aichholzer; C Haberler; W Dietrich; K Dieckmann; W Koos; H Budka
Journal:  J Neurooncol       Date:  1999-04       Impact factor: 4.130

7.  Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.

Authors:  Craig Horbinski; Marina N Nikiforova; Jill M Hagenkord; Ronald L Hamilton; Ian F Pollack
Journal:  Neuro Oncol       Date:  2012-04-05       Impact factor: 12.300

8.  Proliferative activity as measured by MIB-1 labeling index and long-term outcome of cerebellar juvenile pilocytic astrocytomas.

Authors:  Karl Roessler; Alexander Bertalanffy; Hussun Jezan; Achmed Ba-Ssalamah; Irene Slavc; Thomas Czech; Herbert Budka
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

Review 9.  Molecular analysis of pediatric brain tumors.

Authors:  Jaclyn A Biegel; Ian F Pollack
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

10.  MTH-68/H oncolytic viral treatment in human high-grade gliomas.

Authors:  L K Csatary; G Gosztonyi; J Szeberenyi; Z Fabian; V Liszka; B Bodey; C M Csatary
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.